Aggressive silent corticotroph adenoma progressing to pituitary carcinoma. The role of temozolomide therapy
Tóm tắt
Temozolomide (TMZ) has recently been recommended as a novel approach in the management of aggressive pituitary tumors. Herein, we present the case of a 43-year-old man with a 20-year history of silent subtype 2 pituitary corticotroph adenoma. Nine surgical resections and radiotherapy had failed to provide a cure. Morphological evaluation of the tumor revealed a mildly pleomorphic adenoma, the cells of which showed low-level cell proliferative activity with Ki67, increased topoisomerase II alpha index and conclusive O-6-methylguanine-DNA methyltransferase (MGMT) as well as vascular endothelial growth factor (VEGF) immunoreactivity. Given its aggressive behavior and failure of conventional therapy, TMZ was administered. The treatment was continued even after MGMT immunopositivity was identified, but failed to decrease MGMT immunoexpression and exerted no morphologic effect. Examination of the lesion after TMZ therapy showed neither morphologic nor immunohistochemical alterations. In our case, TMZ administration, despite changing the TMZ dosing regimen to prompt a drug response, was incapable of depleting MGMT stores.
Tài liệu tham khảo
Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C, 1997 Temozolomide: A review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 23: 35–61.
Yung WK, 2000 Temozolomide in malignant gliomas. Semin Oncol 27: 27–34.
Hegi ME, Diserens AC, Gorlia T, et al, 2005 MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997–1003.
Levin N, Lavon I, Zelikovitsh B, et al, 2006 Progressive low-grade oligodendrogliomas: Response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer 106: 1759–1765.
Mohammed S, Kovacs K, Mason W, Smyth H, Cusimano MD, 2009 Use of temozolomide in aggressive pituitary tumors: Case report. Neurosurgery 64: E773–774.
Hagen C, Schroeder HD, Hansen S, Hagen C, Andersen M, 2009 Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. Eur J Endocrinol 161: 631–637.
Matsuno A, 2009 Recent trends in the pathophysiology and treatment of pituitary adenomas. Brain Nerve 61: 957–962.
Kovacs K, Horvath E, Syro LV, et al, 2007 Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings. Hum Pathol 38: 185–189.
Agarwala SS, Kirkwood JM, 2000 Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist 5: 144–151.
Kovacs K, Stefaneanu L, Horvath E, et al, 1991 Effect of dopamine agonist medication on prolactin producing pituitary adenomas. A morphological study including immunocytochemistry, electron microscopy and in situ hybridization. Virchows Arch A Pathol Anat Histopathol 418: 439–446.
Kaltsas GA, Mukherjee JJ, Plowman PN, Monson JP, Grossman AB, Besser GM, 1998 The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors. J Clin Endocrinol Metab 83: 4233–4238.
Lamers LM, Stupp R, van den Bent MJ, et al, 2008 Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: A report from the eortc 26981/22981 nci-c ce3 intergroup study. Cancer 112: 1337–1344.
Quirt I, Verma S, Petrella T, Bak K, Charette M, 2007 Temozolomide for the treatment of metastatic melanoma: A systematic review. Oncologist 12: 1114–1123.
Ekeblad S, Sundin A, Janson ET, et al, 2007 Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 13: 2986–2991.
Kovacs K, Scheithauer BW, Lombardero M, et al, 2008 MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathol 115: 261–262.
Neff LM, Weil M, Cole A, et al, 2007 Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists. Pituitary 10: 81–86.
Fadul CE, Kominsky AL, Kingman LS, et al, 2004 Pituitary carcinomas respond to temozolomide. Neuro-Onc 6: 374.
Lim S, Shahinian H, Maya MM, Yong W, Heaney AP, 2006 Temozolomide: A novel treatment for pituitary carcinoma. Lancet Oncol 7: 518–520
Fadul CE, Kominsky AL, Meyer LP, et al, 2006 Long-term response of pituitary carcinoma to temozolomide. Report of two cases. J Neurosurg 105: 621–626.
Maruya S, Shirasaki T, Nagaki T, et al, 2009 Differential expression of topoisomerase II alpha protein in salivary gland carcinomas: Histogenetic and prognostic implications. BMC Cancer 9: 72.
Nakopoulou L, Zervas A, Lazaris AC, et al, 2001 Predictive value of topoisomerase II alpha immunostaining in urothelial bladder carcinoma. J Clin Pathol 54: 309–313.
Lee A, LiVolsi VA, Baloch ZW, 2000 Expression of DNA topoisomerase II alpha in thyroid neoplasia. Mod Pathol 13: 396–400.
Widhalm G, Wolfsberger S, Preusser M, et al, 2009 O(6)-methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas: Are progressive tumors potential candidates for temozolomide treatment? Cancer 115: 1070–1080.
Karavitaki N, Ansorge O, Wass JA, 2007 Silent corticotroph adenomas. Arq Bras Endocrinol Metabol 51: 1314–1318.